YPEG-Somatropin is under clinical development by Xiamen Amoytop Biotech and currently in Phase II for Turner Syndrome. According to GlobalData, Phase II drugs for Turner Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the YPEG-Somatropin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YPEG-somatropin is under development for the treatment of growth hormone deficiency (GHD), born small for gestational age, turner syndrome, idiopathic short stature. The therapeutic candidate is administered through subcutaneous route. It is a pegylated long-acting recombinant human growth hormone developed based on Y-shaped PEGylation modification technique which enables attachment of the linker to the therapeutic moiety with PEG through covalent bond. The therapeutic candidate targets somatropin receptor.
Xiamen Amoytop Biotech overview
Xiamen Amoytop Biotech is a biopharmaceutical company that manufactures, develops and markets recombinant pegylated protein drugs. The company’s product portfolio includes peginterferon Alfa-2b, Molgramostim, filgrastim, oprelvekin and reagents. Its pipeline products include ACT50 and ACT60. Xiamen Amoytop Biotech develops pipeline products for the treatment of cancer, chronic kidney disease, pediatric, angiogenesis-related diseases, hepatitis B and other diseases. It also carries out research and development operations at Xiamen Biosteed Gee Transformation Co Ltd. Xiamen Amoytop Biotech is headquartered in Xiamen, Fujian, China.
For a complete picture of YPEG-Somatropin’s drug-specific PTSR and LoA scores, buy the report here.